POTS and Interstitial Cystitis: The Bladder-Autonomic Connection

Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a chronic condition characterized by bladder pain, urinary urgency, frequency, and pelvic discomfort in the absence of infection. It is another condition that disproportionately affects women, is frequently dismissed or misdiagnosed, and shares biological mechanisms with POTS and MCAS. For patients who have received both diagnoses, understanding the connection between them can illuminate why standard treatments for each condition may need to be modified.

The Prevalence of the Overlap

Bladder dysfunction is well-documented in dysautonomia. The autonomic nervous system controls bladder filling, storage, and emptying through a complex interplay of sympathetic and parasympathetic innervation. When autonomic regulation is impaired — as in POTS — bladder function is frequently affected. Surveys of POTS patients consistently find elevated rates of urinary symptoms including frequency, urgency, and incomplete emptying.

Interstitial cystitis specifically (rather than general urinary dysfunction) appears to be overrepresented in POTS and MCAS populations. The connection is most clearly mediated through mast cell activation: mast cells are found in abundance in the bladder walls of IC patients, where they release histamine and other mediators that cause the inflammation, pain, and hypersensitivity characteristic of the condition. Since MCAS is itself strongly associated with POTS, the three conditions — POTS, MCAS, and IC — frequently cluster together.

Autonomic Control of the Bladder

The bladder is one of the most autonomically innervated organs in the body. Sympathetic nerves (via the hypogastric nerve) promote bladder storage by relaxing the detrusor muscle and contracting the internal urethral sphincter. Parasympathetic nerves (via the pelvic nerve) promote voiding by contracting the detrusor and relaxing the sphincter. Somatic nerves (via the pudendal nerve) control the external urethral sphincter voluntarily.

In POTS, the dysregulation of sympathetic and parasympathetic balance affects this system in several ways. Sympathetic hyperactivation can cause bladder overactivity and urgency. Parasympathetic dysfunction can impair complete bladder emptying, leading to urinary retention and increased infection risk. The orthostatic component of POTS — the redistribution of blood flow upon standing — can also affect renal blood flow and urine production, contributing to urinary frequency.

The Mast Cell Mechanism in IC

The most compelling mechanistic link between IC and POTS/MCAS is mast cell activation. In IC, mast cells in the bladder submucosa release histamine, tryptase, and prostaglandins that damage the bladder's protective glycosaminoglycan (GAG) layer, allowing urinary constituents to irritate the underlying tissue. This creates a cycle of inflammation, pain sensitization, and further mast cell activation.

The same mast cell dysregulation that drives IC also affects the cardiovascular system (through histamine-mediated vasodilation) and the autonomic nervous system (through direct effects on autonomic ganglia). For patients with MCAS, IC may be one of several organ systems affected by systemic mast cell dysregulation, alongside the cardiovascular manifestations of POTS.

Symptom Interactions

The interaction between POTS and IC symptoms creates several clinically important patterns:

Hydration conflict. POTS management requires high fluid intake — typically 2–3 liters per day — to maintain blood volume and orthostatic tolerance. For IC patients, high fluid intake increases urine production and bladder filling, worsening urgency and frequency. This creates a direct conflict between the management of the two conditions. Patients often need to find a balance between adequate hydration for POTS and manageable bladder symptoms, sometimes with the help of timed voiding schedules and bladder training.

IC triggers and POTS flares. Many IC triggers — stress, certain foods, hormonal fluctuations — are also POTS triggers. Stress activates both the sympathetic nervous system (worsening POTS) and mast cells (worsening IC). Hormonal fluctuations around menstruation worsen both conditions simultaneously. Identifying shared triggers can help patients manage both conditions more efficiently.

Pain and autonomic activation. The chronic pain of IC activates the sympathetic nervous system, which can worsen POTS symptoms. Pain is a potent sympathetic stimulus, and patients with poorly controlled IC pain may find that their POTS is harder to manage as a result.

Treatment Considerations

Several IC treatments have implications for POTS management:

Antihistamines: H1 and H2 antihistamines, used for MCAS and sometimes for IC (particularly hydroxyzine, which has evidence for IC), can reduce mast cell-mediated bladder inflammation while also benefiting POTS through their effects on vascular histamine receptors.

Pentosan polysulfate (Elmiron): The only FDA-approved oral medication specifically for IC, pentosan polysulfate works by restoring the bladder's GAG layer. It has no significant cardiovascular effects and is generally safe in POTS patients.

Amitriptyline: A tricyclic antidepressant used for IC pain, amitriptyline has anticholinergic effects that can worsen orthostatic hypotension in POTS patients. It should be used with caution and at the lowest effective dose.

Bladder instillations: Intravesical treatments (medications instilled directly into the bladder) avoid systemic cardiovascular effects and may be preferable for POTS patients who cannot tolerate oral medications that affect blood pressure.

Dietary modification: The IC diet — which avoids acidic, spicy, and caffeinated foods — overlaps partially with dietary modifications that benefit POTS and MCAS. Caffeine, which is sometimes used to improve alertness in POTS, is a bladder irritant in IC and may need to be avoided or minimized.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your treatment plan.